Galmed Pharmaceuticals (GLMD)
(Real Time Quote from BATS)
$8.09 USD
-1.26 (-13.48%)
Updated Sep 24, 2024 11:20 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 41 - 60 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
4Q19 - Still a Buy with Coronavirus Disruptions
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Do Not Forget to Dial-in to Our NASH Call Today with Dr. Arun Sanyal at 1PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Our NASH Expert Call with Dr. Arun Sanyal Moved to Friday, Feb. 21, at 1PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Do Not Forget to Dial-in to Our Call Today with Dr. Arun Sanyal at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Join our Part 2 NASH Call on Feb. 18 with Dr. Arun Sanyal
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Do Not Miss Our NASH Fibrosis Call with Dr. Scott Friedman at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Dial In to Part 1 of Our Three-Part NASH Call Series Tomorrow at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Revisit NASH in 2020: Join Our Three-Part Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare -Join Our 1Q20 Doc Call Series in PWS, NASH, Omega-3s and Contraception
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
NASH Weekly: 2020 Is Packed With Clinical Data Readouts in NASH
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
NASH Weekly: GLP-1 Data in 2Q20 Is Likely to Be Underwhelming
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Part 2: "Must-See" Companies at JPM (Mkt. Cap. $100M-$499M) With 1Q20 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
3Q19 Recap: Expecting Full Clinical Site Activation of Phase 3 ARMOR Study by 2Q20; Raise PT to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
3Q19 - ARMOR Will Bring Strategics from Around the Globe
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - Accelerating the Pace: Perspectives From Our 3rd Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - Should You Attend AASLD in Boston? Use Our Day-By-Day Calendar to Figure It Out
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y